Immune checkpoint inhibitor therapies and allogeneic hematopoietic cell transplant (alloHCT) represent two distinct modalities that offer a chance for long-term cure in a diverse array of malignancies and have experienced many breakthroughs in recent years. Herein, we review the CD27-CD70 co-stimulatory pathway and its therapeutic potential in 1) combination with checkpoint inhibitor and other immune therapies and 2) its potential ability to serve as a novel approach in graft-versus-host disease (GVHD) prevention. We further review recent advances in the understanding of GVHD as a complex immune phenomenon between donor and host immune systems, particularly in the early stages with mixed chimerism, and potential novel therapeutic approaches to prevent the development of GVHD.

免疫检查点抑制剂疗法和同种异体造血细胞移植（alloHCT）代表了两种不同的治疗方式，为多种恶性肿瘤的长期治愈提供了机会，并且近年来取得了许多突破。在此，我们回顾了 CD27-CD70 共刺激途径及其治疗潜力：1）与检查点抑制剂和其他免疫疗法相结合，2）其作为移植物新方法的潜在能力。相对- 宿主疾病（GVHD）预防。我们进一步回顾了 GVHD 作为供体和宿主免疫系统之间的复杂免疫现象的最新进展，特别是在混合嵌合的早期阶段，以及预防 GVHD 发展的潜在新治疗方法。